Heidelberg Pharma‘s patent describes methods to enhance the acceptance of CAR-expressing immune cells in patients with cancer or autoimmune diseases. This involves administering anti-CD5 antibody drug conjugates (ADCs) as a conditioning treatment prior to CAR cell therapy, potentially improving therapeutic outcomes. GlobalData’s report on Heidelberg Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Heidelberg Pharma, Personalized cancer vaccines was a key innovation area identified from patents. Heidelberg Pharma's grant share as of June 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for enhancing car immune cell acceptance using anti-cd5 adcs
The patent US12006370B2 outlines a method for enhancing the acceptance of immune cells expressing chimeric antigen receptors (CARs) in patients with cancer or autoimmune diseases. The method involves administering an anti-CD5 antibody drug conjugate (ADC) that consists of an anti-CD5 antibody linked to a cytotoxin. Following this, a therapeutically effective dose of immune cells expressing a CAR is administered. The CAR is designed to target specific tumor antigens or antigens associated with autoimmune diseases. Notably, the method specifies that patients should not receive alemtuzumab or lymphodepleting chemotherapeutic agents before or during the treatment process, which may include various types of immune cells, such as allogeneic or autologous T cells and NK cells.
Additionally, the patent details the composition of the anti-CD5 ADC, including the types of cytotoxins that can be used, such as antimitotic agents or RNA polymerase inhibitors. The claims also specify the structural components of the CAR, including its extracellular and cytoplasmic domains, which can incorporate various signaling domains. The method is applicable to a wide range of cancers, including leukemia, various solid tumors, and hematological malignancies. The timing of the administration of the immune cells post-ADC treatment is also defined, allowing for a window of 12 hours to 21 days. Overall, this patent presents a comprehensive approach to improving CAR T-cell therapy's efficacy by strategically using an anti-CD5 ADC to prepare the patient's immune environment.
To know more about GlobalData’s detailed insights on Heidelberg Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
